Merus Announces Zenocutuzumab Has Been Granted Breakthrough Therapy Designation By The FDA For NRG1+ Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Merus has announced that its drug Zenocutuzumab has been granted Breakthrough Therapy Designation by the FDA for NRG1+ Pancreatic Cancer. This could potentially expedite the drug's development and review process.
June 29, 2023 | 8:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus's drug Zenocutuzumab has been granted Breakthrough Therapy Designation by the FDA. This could potentially expedite the drug's development and review process, which may positively impact the company's stock.
The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The designation for Merus's Zenocutuzumab means that the drug could potentially reach the market sooner, which could lead to increased revenues for the company and a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100